Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively.

Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction
2. Gorlin Syndrome (Basal Cell Nevus Syndrome) - Overview
3. Gorlin Syndrome (Basal Cell Nevus Syndrome) - Therapeutics Development
4. Pipeline Overview
5. Pipeline by Companies
6. Products under Development by Companies
7. Gorlin Syndrome (Basal Cell Nevus Syndrome) - Therapeutics Assessment
8. Assessment by Target
9. Assessment by Mechanism of Action
10. Assessment by Route of Administration
11. Assessment by Molecule Type
12. Gorlin Syndrome (Basal Cell Nevus Syndrome) - Companies Involved in Therapeutics Development

• Adgero Biopharmaceuticals Holdings Inc
• Galderma SA
• Mayne Pharma Group Ltd
• Transgene SA

For more information about this report visit https://www.researchandmarkets.com/research/29r7fz/gorlin_syndrome